James T. Parsons - Net Worth and Insider Trading
James T. Parsons Net Worth
The estimated net worth of James T. Parsons is at least $24,827 dollars as of 2024-09-20. James T. Parsons is the Director of DiaMedica Therapeutics Inc and owns about 6,100 shares of DiaMedica Therapeutics Inc (DMAC) stock worth over $24,827. James T. Parsons is also the CFO of Trillium Therapeutics Inc and owns about 0 shares of Trillium Therapeutics Inc (TRIL) stock worth over $0. Details can be seen in James T. Parsons's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James T. Parsons has not made any transactions after 2021-01-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of James T. Parsons
James T. Parsons Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, James T. Parsons owns 1 companies in total, including DiaMedica Therapeutics Inc (DMAC) .
Click here to see the complete history of James T. Parsons’s form 4 insider trades.
Insider Ownership Summary of James T. Parsons
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| DMAC | DiaMedica Therapeutics Inc | 2018-12-11 | director |
James T. Parsons Latest Holdings Summary
James T. Parsons currently owns a total of 2 stocks. Among these stocks, James T. Parsons owns 6,100 shares of DiaMedica Therapeutics Inc (DMAC) as of December 11, 2018, with a value of $24,827 and a weighting of 100%. James T. Parsons also owns 0 shares of Trillium Therapeutics Inc (TRIL) as of January 8, 2021, with a value of $0 and a weighting of 0%.
Latest Holdings of James T. Parsons
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| DMAC | DiaMedica Therapeutics Inc | 2018-12-11 | 6,100 | 4.07 | 24,827 |
| TRIL | Trillium Therapeutics Inc | 2021-01-08 | 0 | 18.44 | 0 |
Holding Weightings of James T. Parsons
James T. Parsons Form 4 Trading Tracker
According to the SEC Form 4 filings, James T. Parsons has made a total of 0 transactions in DiaMedica Therapeutics Inc (DMAC) over the past 5 years. The most-recent trade in DiaMedica Therapeutics Inc is the acquisition of 2,250 shares on December 11, 2018, which cost James T. Parsons around $9,000.
According to the SEC Form 4 filings, James T. Parsons has made a total of 1 transactions in Trillium Therapeutics Inc (TRIL) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Trillium Therapeutics Inc is the sale of 8,505 shares on January 8, 2021, which brought James T. Parsons around $134,294.
Insider Trading History of James T. Parsons
- 1
James T. Parsons Trading Performance
GuruFocus tracks the stock performance after each of James T. Parsons's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James T. Parsons is -7.24%. GuruFocus also compares James T. Parsons's trading performance to market benchmark return within the same time period. The performance of stocks bought by James T. Parsons within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how James T. Parsons's insider trading performs compared to the benchmark.
Performance of James T. Parsons
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -1.39 | | | | | |
| Relative Return to S&P 500(%) | 0.15 | | | | | |
James T. Parsons Ownership Network
James T. Parsons Owned Company Details
What does DiaMedica Therapeutics Inc do?
Who are the key executives at DiaMedica Therapeutics Inc?
James T. Parsons is the director of DiaMedica Therapeutics Inc. Other key executives at DiaMedica Therapeutics Inc include 10 percent owner Jan Stahlberg , 10 percent owner Koch Thomas Von , and CFO and Secretary Scott Kellen .
DiaMedica Therapeutics Inc (DMAC) Insider Trades Summary
Over the past 18 months, James T. Parsons made no insider transaction in DiaMedica Therapeutics Inc (DMAC). Other recent insider transactions involving DiaMedica Therapeutics Inc (DMAC) include a net purchase of 527,114 shares made by David J. Wambeke , a net purchase of 2,670,588 shares made by Koch Thomas Von , and a net purchase of 1,200,000 shares made by Jan Stahlberg .
In summary, during the past 3 months, insiders sold 0 shares of DiaMedica Therapeutics Inc (DMAC) in total and bought 2,400,000 shares, with a net purchase of 2,400,000 shares. During the past 18 months, 0 shares of DiaMedica Therapeutics Inc (DMAC) were sold and 4,536,639 shares were bought by its insiders, resulting in a net purchase of 4,536,639 shares.
DiaMedica Therapeutics Inc (DMAC)'s detailed insider trading history can be found in Insider Trading Tracker table.
DiaMedica Therapeutics Inc Insider Transactions
James T. Parsons Mailing Address
Above is the net worth, insider trading, and ownership report for James T. Parsons. You might contact James T. Parsons via mailing address: 2 Carlson Parkway, Suite 260, Minneapolis Mn 55447.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
